Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics.

ABSTRACT:

Introduction

The prevalence of obesity is increasing globally. The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability and pharmacokinetic (PK) parameters of omeprazole.

Methods

Controlled, open-label, bioavailability clinical trial in patients undergoing Roux-en-Y gastric bypass (RYGB). Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months). PK sampling was done at baseline and several times up to 12 h after drug dosing. Pre- and post-surgery parameters were compared using paired ANOVA or Wilcoxon tests, and control versus cases using ANOVA or Mann-Whitney tests. Given the post-surgery change in body weight, parameters were corrected by dose/body weight.

SUBMITTER: Portoles-Perez A 

PROVIDER: S-EPMC9021662 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature